UCSF-CAPRA Score for Prostate Cancer
Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence, metastasis, and cancer-specific death after prostatectomy. Score 0–2 = low risk; 3–5 = intermediate; 6–10 = high risk.
Score interpretation
CAPRA 0–2 — low risk. 5-year recurrence-free survival after prostatectomy 85 % for CAPRA 0–1 (Cooperberg 2005).
→ Active surveillance appropriate option; if treating, nerve-sparing prostatectomy or radiotherapy; PSA monitoring
CAPRA 3–5 — intermediate risk; the risk of recurrence roughly doubles with each 2-point rise.
→ Radical prostatectomy or radiotherapy + short-term ADT; multiparametric MRI; urology MDT discussion
CAPRA 6–10 — high risk. 5-year recurrence-free survival after prostatectomy 8 % for CAPRA 7–10 (Cooperberg 2005).
→ Radiotherapy + long-term ADT (2–3 years) or radical prostatectomy with pelvic lymph node dissection; clinical trial eligibility
Interpretation bands for the CAPRA Score. Apply clinical judgement and local guidance.
References
- Cooperberg MR et al. The UCSF cancer of the prostate risk assessment (CAPRA) score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938–1942.
Related
Curated clinical cross-links plus same-class fallbacks.
- Gleason Score / Grade Group for Prostate Cancer · Prostate Cancer
- Prostate Cancer Risk Groups (EAU) · Prostate Cancer
- PSA Doubling Time (PSADT) Calculator · Prostate Cancer
- D'Amico Risk Classification for Prostate Cancer · Prostate Cancer
- PSA Velocity and PSA Density · Prostate Cancer
- D'Amico Risk Stratification for Localised Prostate Cancer · Prostate Cancer
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.